Is there a correlation between biomarkers and long term sapropterin success?

How do biomarkers help predict who responds to sapropterin?

Sapropterin is a synthetic form of tetrahydrobiopterin (BH4), a cofactor required for phenylalanine hydroxylase (PAH) to convert phenylalanine into tyrosine. The drug lowers blood phenylalanine in patients with phenylketonuria (PKU) who retain some residual PAH activity. Biomarker measurements guide initial selection of candidates and help monitor ongoing response. A 20-30% drop in blood phenylalanine after a one-month trial is the current clinical threshold for defining a sapropterin responder.

What blood phenylalanine patterns emerge during a sapropterin trial?

Blood phenylalanine levels fall quickly in responders—within days to weeks—while non-responders show no significant change. The 20-30% reduction threshold has been used in clinical trials and approved labeling. Approved doses range from 5 to 20 mg/kg/day. The pattern of decline is consistent in patients whose PAH gene mutations still allow partial enzyme activity.

What other biomarkers help identify responders?

Genetic testing for PAH mutations provides the stärkste predictor. Patients with certain milder mutations show 80-100% probability of response. Milder variants such as p.R408W and p.Y414C are among those identified as responsive. Milder variants in the regulatory domain rather than the catalytic domain tend to respond. The combination of a sapropterin challenge test plus genetic results improves accuracy.

How does lang lang long-term success look with sapropterin?

Long-term success means sustained phenylalanine control,<|eos|>